Can toddlers get three vaccines at once? new study says yes
NCT ID NCT06442449
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving a booster polio vaccine (sIPV) at the same time as MMR and hepatitis A vaccines is safe and works well in toddlers. About 889 healthy children aged 18 to 22 months who had already received their first polio and MMR shots took part. Researchers checked immune responses and side effects 30 days after vaccination.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Sabin strain inactivated poliovirus vaccine (sIPV), measles-mumps-rubella (MMR) vaccine, and inactivated hepatitis A (HepA-I) vaccine
- What this could lead to
- If successful, this could show that giving these booster vaccines together is safe and effective, simplifying childhood immunization schedules.
- What could go wrong
- This is a completed Phase 4 trial, so results are already known. The main risk is that co-administration might lower immune response or increase side effects compared to separate shots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
889 people
The number who actually took part.
- Started
-
Aug 2024
- Finished
-
Oct 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 22 months
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * (1) healthy toddlers aged 18 months (+4 months); * (2) completed three doses of sIPV primary immunization; * (3) completed one dose of MMR vaccination; * (4) able to provide proof of vaccination; * (5) able to provide legal proof of identity; * (6) The guardians of the participants were able to understand and agree to sign the informed consent. Exclusion Criteria: * (1) a history of vaccination with a polio-containing vaccine component in addition to three sIPV primary doses, according to the vaccination certificate; * (2) have received a second dose of MMR vaccine or a vaccine containing a vaccine for measles, mumps or rubella, or hepatitis A vaccine (inactivated or attenuated), according to the vaccination certificate; * (3) previous history of polio or measles or mumps or rubella or hepatitis A; * (4) known severe allergy to the vaccine or vaccine components, such as urticaria, dyspnea, angioedema; * (5) severe congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; * (6) with autoimmune diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, asplenia, functional asplenia, and HIV infection); * (7) abnormal coagulation function (such as coagulation factor deficiency, platelet abnormality), or obvious bleeding, hematoma, or ecchymosis after previous intramuscular injection or venipuncture; * (8) have/have had a serious neurological disease (e.g., encephalopathy, epilepsy, convulsions \[other than febrile convulsions\]) or psychosis, a family history of neurological disease or psychosis; * (9) receiving immunosuppressive or other immunomodulatory therapy, cytotoxic therapy within the past 6 months, or planning to receive such treatment during the trial; * (10) have received an immune globulin or other blood products within the past 6 months or plan to receive such treatment during the trial; * (11) receipt of other investigational vaccines within 30 days before vaccination with the investigational vaccines; * (12) receipt of live attenuated vaccine within 28 days before vaccination with the investigational vaccine; * (13) receipt of subunit or inactivated vaccine within 7 days before vaccination with the investigational vaccine; * (14) acute diseases or acute episodes of chronic diseases within the past 7 days; * (15) Axillary temperature \>37.0℃ if fever occurred before vaccination; * (16) which are unsuitable for participation in the clinical trial as judged by the investigators.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Poliomyelitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Center for Disease Control and Prevention (Jiangsu Institute of Public Health)
Nanjing, Jiangsu, 210009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can virtual walking trick the brain into easing chronic pain?
- Can a Birth-Dose polio vaccine block the virus in Babies' guts?
- One shot, six protections: could a single vaccine replace multiple infant shots?
- Can a new polio vaccine stop the virus at the throat?
- Can one shot replace six? a new vaccine aims to protect infants from six diseases at once
- One shot, six protections: can a new vaccine match current standards?